Header Logo

Connection

VASSILIKI A PAPADIMITRAKOPOULOU to Carcinoma, Non-Small-Cell Lung

Back to Details
This is a "connection" page, showing publications VASSILIKI A PAPADIMITRAKOPOULOU has written about Carcinoma, Non-Small-Cell Lung.
VASSILIKI A PAPADIMITRAKOPOULOU
Connection Strength
5.564
Carcinoma, Non-Small-Cell Lung
  1. Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial. Nat Commun. 2023 02 27; 14(1):1071.
    View in: PubMed
    Score: 0.261
  2. SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study). Clin Lung Cancer. 2021 05; 22(3):178-186.
    View in: PubMed
    Score: 0.223
  3. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. Ann Oncol. 2020 11; 31(11):1536-1544.
    View in: PubMed
    Score: 0.220
  4. Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer. Cancer. 2020 01 15; 126(2):373-380.
    View in: PubMed
    Score: 0.209
  5. SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study). J Thorac Oncol. 2019 10; 14(10):1839-1846.
    View in: PubMed
    Score: 0.202
  6. New Treatment Options in Advanced Squamous Cell Lung Cancer. Am Soc Clin Oncol Educ Book. 2019 Jan; 39:e198-e206.
    View in: PubMed
    Score: 0.201
  7. Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer. Clin Cancer Res. 2019 Aug 01; 25(15):4691-4700.
    View in: PubMed
    Score: 0.200
  8. Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study. Lung Cancer. 2018 11; 125:273-281.
    View in: PubMed
    Score: 0.191
  9. Targeting the Gatekeeper: Osimertinib in EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer. Clin Cancer Res. 2017 Feb 01; 23(3):618-622.
    View in: PubMed
    Score: 0.169
  10. Personalized Medicine Tackles Clinical Resistance: Alectinib in ALK-Positive Non-Small Cell Lung Cancer Progressing on First-Generation ALK Inhibitor. Clin Cancer Res. 2016 Nov 01; 22(21):5177-5182.
    View in: PubMed
    Score: 0.167
  11. Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400. Clin Cancer Res. 2015 Apr 01; 21(7):1514-24.
    View in: PubMed
    Score: 0.150
  12. Ceritinib for the treatment of late-stage (metastatic) non-small cell lung cancer. Clin Cancer Res. 2015 Feb 15; 21(4):670-4.
    View in: PubMed
    Score: 0.149
  13. The importance of molecular profiling in predicting response to epidermal growth factor receptor family inhibitors in non-small-cell lung cancer: focus on clinical trial results. Clin Lung Cancer. 2013 Jul; 14(4):311-21.
    View in: PubMed
    Score: 0.132
  14. Uncommon epidermal growth factor receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance. Lung Cancer. 2013 Jun; 80(3):235-41.
    View in: PubMed
    Score: 0.131
  15. Phosphatidykinosital 3-kinase and mammalian target of rapamycin pathway in non-small-cell lung cancer. J Thorac Oncol. 2012 Dec; 7(16 Suppl 5):S379-82.
    View in: PubMed
    Score: 0.129
  16. Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer. J Thorac Oncol. 2012 Oct; 7(10):1594-601.
    View in: PubMed
    Score: 0.127
  17. Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer. J Thorac Oncol. 2012 Aug; 7(8):1315-26.
    View in: PubMed
    Score: 0.126
  18. The future of NSCLC: molecular profiles guiding treatment decisions. Oncology (Williston Park). 2011 Jun; 25(7):607, 614.
    View in: PubMed
    Score: 0.116
  19. Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Ann Oncol. 2009 Oct; 20(10):1674-81.
    View in: PubMed
    Score: 0.101
  20. Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1-Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial. J Thorac Oncol. 2023 08; 18(8):1094-1102.
    View in: PubMed
    Score: 0.066
  21. Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I. J Natl Cancer Inst. 2023 04 11; 115(4):437-446.
    View in: PubMed
    Score: 0.066
  22. Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A. J Clin Oncol. 2022 07 20; 40(21):2295-2306.
    View in: PubMed
    Score: 0.062
  23. Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non-Small Cell Lung Cancer. Clin Lung Cancer. 2022 01; 23(1):72-81.
    View in: PubMed
    Score: 0.059
  24. Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021 Sep 01; 7(9):1368-1377.
    View in: PubMed
    Score: 0.059
  25. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. J Immunother Cancer. 2021 08; 9(8).
    View in: PubMed
    Score: 0.059
  26. Patient Knowledge and Expectations About Return of Genomic Results in a Biomarker-Driven Master Protocol Trial (SWOG S1400GEN). JCO Oncol Pract. 2021 11; 17(11):e1821-e1829.
    View in: PubMed
    Score: 0.057
  27. Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G. Clin Lung Cancer. 2021 05; 22(3):187-194.e1.
    View in: PubMed
    Score: 0.056
  28. Genotype-Specific Differences in Circulating Tumor DNA Levels in Advanced NSCLC. J Thorac Oncol. 2021 04; 16(4):601-609.
    View in: PubMed
    Score: 0.056
  29. Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol. Lancet Oncol. 2020 12; 21(12):1589-1601.
    View in: PubMed
    Score: 0.056
  30. The value of interventional radiology in clinical trial teams: experience from the BATTLE lung cancer trials. Clin Radiol. 2021 Feb; 76(2):155.e25-155.e34.
    View in: PubMed
    Score: 0.056
  31. A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753). Clin Lung Cancer. 2021 05; 22(3):170-177.
    View in: PubMed
    Score: 0.055
  32. Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02). Cancer Discov. 2020 08; 10(8):1158-1173.
    View in: PubMed
    Score: 0.054
  33. Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. J Thorac Oncol. 2020 09; 15(9):1449-1459.
    View in: PubMed
    Score: 0.054
  34. Locoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Non-Small-Cell Lung Cancer: Analysis of Resected and Unresected Patients. Clin Lung Cancer. 2020 07; 21(4):e294-e301.
    View in: PubMed
    Score: 0.053
  35. Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations. Expert Rev Respir Med. 2020 02; 14(2):125-136.
    View in: PubMed
    Score: 0.052
  36. SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy). J Thorac Oncol. 2019 10; 14(10):1853-1859.
    View in: PubMed
    Score: 0.051
  37. SWOG S1400D (NCT02965378), a Phase II Study of?the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage?IV Squamous Cell Lung Cancer (Lung-MAP?Substudy). J Thorac Oncol. 2019 10; 14(10):1847-1852.
    View in: PubMed
    Score: 0.051
  38. PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer. J Thorac Oncol. 2019 06; 14(6):1021-1031.
    View in: PubMed
    Score: 0.049
  39. Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation. J Thorac Oncol. 2019 03; 14(3):553-559.
    View in: PubMed
    Score: 0.049
  40. Validation of the 12-gene Predictive Signature for Adjuvant Chemotherapy Response in Lung Cancer. Clin Cancer Res. 2019 01 01; 25(1):150-157.
    View in: PubMed
    Score: 0.048
  41. Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non-small-cell Lung Cancer (NSCLC). Clin Lung Cancer. 2019 01; 20(1):43-47.
    View in: PubMed
    Score: 0.048
  42. Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC. Clin Cancer Res. 2018 12 15; 24(24):6195-6203.
    View in: PubMed
    Score: 0.048
  43. 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for?Advanced Nonsquamous Non-Small Cell Lung?Cancer. J Thorac Oncol. 2019 01; 14(1):124-129.
    View in: PubMed
    Score: 0.048
  44. CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3). J Clin Oncol. 2018 09 10; 36(26):2702-2709.
    View in: PubMed
    Score: 0.048
  45. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). J Immunother Cancer. 2018 07 17; 6(1):75.
    View in: PubMed
    Score: 0.047
  46. CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade. Cancer Discov. 2018 09; 8(9):1156-1175.
    View in: PubMed
    Score: 0.047
  47. Patient-reported symptoms possibly related to treatment with osimertinib or chemotherapy for advanced non-small cell lung cancer. Lung Cancer. 2018 08; 122:100-106.
    View in: PubMed
    Score: 0.047
  48. Targeted Therapy and Immunotherapy in the Treatment of Non-Small Cell Lung Cancer. Radiol Clin North Am. 2018 May; 56(3):485-495.
    View in: PubMed
    Score: 0.047
  49. Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med. 2018 05; 24(5):638-646.
    View in: PubMed
    Score: 0.047
  50. Immunotherapy in Non-Small Cell Lung Cancer Treatment: Current Status and the Role of Imaging. J Thorac Imaging. 2017 Sep; 32(5):300-312.
    View in: PubMed
    Score: 0.045
  51. Targeted Therapy and Imaging Findings. J Thorac Imaging. 2017 Sep; 32(5):313-322.
    View in: PubMed
    Score: 0.045
  52. JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non-Small Cell Lung Cancer. Mol Cancer Ther. 2017 10; 16(10):2234-2245.
    View in: PubMed
    Score: 0.044
  53. Comprehensive evaluation of published gene expression prognostic signatures for biomarker-based lung cancer clinical studies. Ann Oncol. 2017 04 01; 28(4):733-740.
    View in: PubMed
    Score: 0.043
  54. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. 2017 02 16; 376(7):629-640.
    View in: PubMed
    Score: 0.042
  55. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016 Nov; 17(11):1497-1508.
    View in: PubMed
    Score: 0.042
  56. Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer. Lung Cancer. 2016 09; 99:79-87.
    View in: PubMed
    Score: 0.041
  57. Innovative Clinical Trials: The LUNG-MAP Study. Clin Pharmacol Ther. 2015 May; 97(5):488-91.
    View in: PubMed
    Score: 0.038
  58. Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2015 Apr 30; 372(18):1700-9.
    View in: PubMed
    Score: 0.038
  59. Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer. Ann Oncol. 2014 Feb; 25(2):409-15.
    View in: PubMed
    Score: 0.035
  60. Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer. Invest New Drugs. 2014 Feb; 32(1):123-34.
    View in: PubMed
    Score: 0.033
  61. Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy. J Thorac Oncol. 2013 Feb; 8(2):222-8.
    View in: PubMed
    Score: 0.033
  62. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst. 2012 Feb 08; 104(3):228-39.
    View in: PubMed
    Score: 0.030
  63. Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. J Thorac Oncol. 2011 Dec; 6(12):2104-11.
    View in: PubMed
    Score: 0.030
  64. Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. PLoS One. 2010 Nov 29; 5(11):e14124.
    View in: PubMed
    Score: 0.028
  65. Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). Invest New Drugs. 2011 Jun; 29(3):499-505.
    View in: PubMed
    Score: 0.026
  66. The Akt/mTOR and mitogen-activated protein kinase pathways in lung cancer therapy. J Thorac Oncol. 2006 Sep; 1(7):749-51.
    View in: PubMed
    Score: 0.021
  67. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 2):4441s-4445s.
    View in: PubMed
    Score: 0.021
  68. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer. 2005 Dec 01; 104(11):2449-56.
    View in: PubMed
    Score: 0.020
  69. Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer. Clin Cancer Res. 2005 Aug 15; 11(16):6065-74.
    View in: PubMed
    Score: 0.019
  70. Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma. Cancer. 2005 Aug 01; 104(3):561-9.
    View in: PubMed
    Score: 0.019
  71. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys. 2004 Apr 01; 58(5):1369-77.
    View in: PubMed
    Score: 0.018
  72. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res. 2003 Jan; 9(1):93-101.
    View in: PubMed
    Score: 0.016
  73. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy. Cancer. 2002 Jul 15; 95(2):340-53.
    View in: PubMed
    Score: 0.016
  74. Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results. Semin Radiat Oncol. 2002 Jan; 12(1 Suppl 1):46-9.
    View in: PubMed
    Score: 0.015
  75. TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer. J Clin Invest. 2018 06 01; 128(6):2500-2518.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.